The Covid pill: new antiviral taskforce faces tough challenge
Boris Johnson’s government launches bid to find medication to treat coronavirus at home
A new taskforce is to lead the UK’s search for a home antiviral treatment such as a pill or capsule that can help prevent Covid-19 patients from becoming seriously ill.
Announcing the plan at a Downing Street press briefing yesterday, Boris Johnson said he hoped a “Covid pill” would be available by the autumn to help combat any third wave of the virus.
But, as The Times says, developing antiviral treatments has so far “proved difficult”.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
‘A lot of work’
Nat Moorman, a virologist at the University of North Carolina at Chapel Hill, told Nature last week that “a lot of work” needs to be done to find an antiviral treatment for the coronavirus. The journal reports that despite previous outbreaks of Sars and Mers, there have been “practically no strong antiviral drug candidates to quickly test and deploy against Sars-CoV-2”, the virus that causes Covid-19.
The candidates that have been considered include remdesivir, originally developed to treat hepatitis C and Ebola. But Nature says that “some clinical studies have failed to confirm that it offers [Covid] patients any benefit. And the drug is expensive, difficult to manufacture and must be given intravenously in a hospital - all undesirable attributes in the middle of a pandemic.”
Experts are hoping that some of those issues might be avoided with another antiviral drug, molnupiravir, which is undergoing early-stage testing in hamsters by the US National Institutes of Health (NIH) and late-stage human trials by biotech company Ridgeback Biotherapeutics and pharmaceutical Merck. Meanwhile, the NHS is testing an antiviral called favipiravir in trials involving UK patients.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Targeting the problem
Developing antiviral treatments is hard is “because viruses offer far fewer targets than bacteria to attack”, says The Times.
While bacteria are whole living cells, “viral pathogens live inside our own cells and depend on our proteins for most of their needs”, explains Scientific American. There are also few natural antivirals, “so scientists have to invent them from scratch”, the science magazine continues.
The challenge for antiviral designers is “to stop the virus without damaging the inner workings of healthy cells too”.
The good news
Johnson said yesterday that he hopes that at least two effective treatments will be developed to provide “another vital defence against any future increase in infections”. The aim is to have an antiviral pill or capsule that can be taken at home by people who have tested positive for Covid or has been exposed to the virus.
Patrick Vallance, the government's chief scientific adviser, pointed to the speed at which the vaccines and other treatments such as the steroid dexamethasone were found and rolled out. “The taskforce will help ensure the most promising antivirals are available for deployment as quickly as possible,” he said.
Create an account with the same email registered to your subscription to unlock access.
-
Who actually needs life insurance?
The Explainer If you have kids or are worried about passing on debt, the added security may be worth it
By Becca Stanek, The Week US Published
-
Sexual wellness trends to know, from products and therapies to retreats and hotels
The Week Recommends Talking about pleasure and sexual health is becoming less taboo
By Theara Coleman, The Week US Published
-
Is the AI bubble deflating?
Today's Big Question Growing skepticism and high costs prompt reconsideration
By Joel Mathis, The Week US Published
-
Covid four years on: have we got over the pandemic?
Today's Big Question Brits suffering from both lockdown nostalgia and collective trauma that refuses to go away
By Chas Newkey-Burden, The Week UK Published
-
The hollow classroom
Opinion Remote school let kids down. It will take much more than extra tutoring for kids to recover.
By Mark Gimein Published
-
Excess screen time is making children only see what is in front of them
Under the radar The future is looking blurry. And very nearsighted.
By Devika Rao, The Week US Published
-
Covid-19: what to know about UK's new Juno and Pirola variants
in depth Rapidly spreading new JN.1 strain is 'yet another reminder that the pandemic is far from over'
By Arion McNicoll, The Week UK Published
-
Long-term respiratory illness is here to stay
The Explainer Covid is not the only disease with a long version
By Devika Rao, The Week US Published
-
Covid inquiry: the most important questions for Boris Johnson
Talking Point Former PM has faced weeks of heavy criticism from former colleagues at the public hearing
By The Week Staff Published
-
China's pneumonia cases: should we be worried?
The Explainer Experts warn against pushing 'pandemic panic button' following outbreak of respiratory illness
By Keumars Afifi-Sabet, The Week UK Published
-
Vallance diaries: Boris Johnson 'bamboozled' by Covid science
Speed Read Then PM struggled to get his head around key terms and stats, chief scientific advisor claims
By The Week UK Published